-
Sarah Aitchison
Incubation ManagervHive University of Surrey -
Sven Arnouts
Business DevelopmentGhent University -
Karl Aschenbrücker
Associate PartnerMcKinsey & Company -
Phil Austin
Managing Partner & Co-FounderAnterra Capital -
Tim Bettington
Executive Vice President, Corporate Strategy & Market DevelopmentElanco -
Greg Blair
Vice President of Business DevelopmentZomedica -
Jamie Brannan
Executive Vice President and Chief Commercial OfficerZoetis -
Sandra Bruckner
Managing DirectorAstraSana Animal Health AG -
Hui Cai
Senior Vice President, Head of Clinical ManufacturingWuXi Biologics -
Paul Casady
Senior ConsultantBrakke Consulting -
Louisa Chaves
PrincipalL.E.K Consulting -
Justine Conway
Vice President of Business Development & External InnovationElanco -
Ellen de Brabander
Executive Vice President R&D and InnovationElanco -
Paul Dick
PresidentPaul Dick & AssociatesDr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.). -
Tom Diethe
Head of The Centre for Artificial IntelligenceAstraZeneca -
Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business DevelopmentZoetisRimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.
-
Pierre Ducray
Vice President, Global Technical Development,Elanco -
Roxanne Feller
Secretary GeneralAnimal Health Europe -
Michael Fitzke
Senior Director AI, Next Generation TechnologiesMars Science & Diagnostics -
Angelo Gatto
CEOChanelle Pharma -
Megan Grether
Head of Global Business Development and Licensing Animal HealthBoehringer Ingelheim -
Adrian Grosu
Partner, SC AnalyticsStonehaven Cozmix Group -
Dr Eve Hanks
Chief Executive Officer & FounderMI:RNA Diagnostics -
Joe Harvey
Head of Animal HealthS&P Global -
Dr. Lourens Havenga
Senior ConsultantBrakke Consulting -
Mark Heffernan
Senior VP of Biotherapeutics and CEO of Ceva Biotechnology Campus (Philadelphia)Ceva -
Charles Hoare
Managing Director, Head of European Healthcare M&AStifelCharles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
-
Matthias Hofer
Managing PartnerStonehaven Cozmix GroupMatthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
-
Jürgen Horn
CEOInvetx -
Andreas Kastenbauer
PartnerMIG Capital -
Rob Kelly
Senior Vice President, Commercial Leader for EURAM RegionMSD Animal Health -
Kathryn Kukla
Founder & Managing PartnerAnimal Health Experts -
Sebastian Kusmierczyk
Vice President, Corporate & Global Innovation StrategyElanco -
Julie Lawless
PresidentLawless Strategic Communications -
Alan Mackay
Managing Partner and FounderGHO Capital -
Natalie Marks
Executive CommitteeVANE -
Jan Moehlenbrock
Associate Vice President, Operations EURAMMSD Animal Health -
Philippe Moreau
DirectorAnimal Health Angels -
Lourdes Mottier
Business Development Head of Strategy & Chief of StaffElanco -
Nicolas Naillon
Managing Director, Head of Healthcare EMEANomura -
Steve Nanchen
Senior Director, External Innovation EU & APAC PacificElanco -
Jesper Nordengaard
CEODechra -
Ron Phillips
Senior Vice President, PolicyAnimal Health Institute -
Todd Richter
Senior Managing DirectorGuggenheim Partners -
Carel du Marchie Sarvaas
Executive DirectorHealthforAnimals Global Animal Health AssociationCarel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
-
Aaron Schacht
CEOBiomEdit -
Tom Seaman
Senior Advisor, Business DevelopmentElanco -
Robert Shrimsley
Editor DirectorialFinancial Times -
Jeff Simmons
Chief Executive OfficerElanco -
Emmanuelle Soubeyran
Director GeneralWorld Organisation for Animal Health -
Julia Stephanus
PartnerBorealis VenturesJulia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
-
Navann Ty
Lead Analyst for HealthcareBNP Paribas -
Brandon Vasquez
Research Analyst, HealthcareWilliam Blair -
Beatrice Vos, PhD
PartnerStonehaven Cozmix Group (and CEO @ SC Transactions AG) -
Tom Weaver
Co-Founder, PetMedix & DirectorBlackHawk Innovation -
Dave Westenberg
Managing Director Equity ResearchPiper Sandler -
Adrienne Woodward
Senior Manager - Discovery & Novel ProductsUnited Animal Health -
Todd Zion
CEO and ChairmanAkston Biosciences